Matthew E Kennedy

List of Publications by Year
in descending order

13	1,559	840776 11	1125743 13
papers	citations	h-index	g-index

14	14	14	2625
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Design and discovery of C2-fluoroalkyl iminothiazine dioxides as BACE inhibitors. Bioorganic and Medicinal Chemistry Letters, 2022, 56, 128463.	2.2	0
2	Characterization of the Onset, Progression, and Reversibility of Morphological Changes in Mouse Lung after Pharmacological Inhibition of Leucine-Rich Kinase 2 Kinase Activity. Journal of Pharmacology and Experimental Therapeutics, 2021, 377, 11-19.	2.5	16
3	Gga3 deletion and a GGA3 rare variant associated with late onset Alzheimerâ€™s disease trigger BACE1 accumulation in axonal swellings. Science Translational Medicine, 2020, 12, .	12.4	11
4	Tau molecular diversity contributes to clinical heterogeneity in Alzheimerâ€™s disease. Nature Medicine, 2020, 26, 1256-1263.	30.7	262
5	LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits. Science Translational Medicine, 2020, 12, .	12.4	85
6	BACE1 partial deletion induces synaptic plasticity deficit in adult mice. Scientific Reports, 2019, 9, 19877.	3.3	25
7	Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity. Journal of Medicinal Chemistry, 2017, 60, 2983-2992.	6.4	113
8	Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-AÎ²PPswe Mice Without Inducing Microhemorrhage. Journal of Alzheimer's Disease, 2017, 59, 1393-1413.	2.6	24
9	Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)â€“A Î²-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimerâ€™s Disease. Journal of Medicinal Chemistry, 2016, 59, 10435-10450.	6.4	126
10	The BACE1 inhibitor verubecestat (MK-8931) reduces CNS Î²-amyloid in animal models and in Alzheimerâ€™s disease patients. Science Translational Medicine, 2016, 8, 363ra150.	12.4	352
11	Structure-Based Design of an Iminoheterocyclic Î²-Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central Aî² in Nonhuman Primates. Journal of Medicinal Chemistry, 2016, 59, 3231-3248.	6.4	36
12	MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition. Journal of Pharmacology and Experimental Therapeutics, 2015, 355, 397-409.	2.5	234
13	Function, therapeutic potential and cell biology of <scp>BACE</scp> proteases: current status and future prospects. Journal of Neurochemistry, 2014, 130, 4-28.	3.9	269